Can-Fite BioPharma Ltd.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Motti Farbstein
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10 Bareket Street Ramat Gan Israel 4951778
- IPO Date
- Nov 6, 2012
- CIK
- 0001536196
- Website
- canfite.com
- Similar Companies
- Business
- Can-Fite BioPharma Ltd. (NYSE American: CANF) develops and commercializes oral and injectable small molecule drugs that address inflammatory diseases, liver, and certain cancers via the A3 adenosine receptor, a novel biological target; its lead product candidate, Piclidenoson (CF101), is an orally bioavailable drug in advanced clinical development for the treatment of plaque psoriasis, rheumatoid arthritis, and dry eye syndrome; additional pipeline candidates include Namodenoson (CF602), targeting non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other liver diseases, and Lisofylline (CF1124) for reducing inflammation and treating inflammatory lung diseases such as acute lung injury and COVID-19 complications. The company operates primarily in the biotechnology sector, focusing on immuno-inflammatory indications and oncology, with clinical-stage assets targeting patients suffering from autoimmune disorders, liver conditions, and solid tumors; it serves pharmaceutical partners and conducts trials across multiple geographies including the United States, Europe, and Israel. Founded in 1994 and headquartered in Petach-Tikva, Israel, Can-Fite maintains subsidiaries such as OphthaliX Inc. for ophthalmic applications. In recent developments, Can-Fite entered a strategic licensing agreement with Enterin Inc. in 2024 for global rights to develop and commercialize Anavex 2-73 for ALS treatment, marking a significant pipeline expansion into neurodegenerative diseases; the company also reported positive topline results from a Phase IIb trial of Namodenoson in advanced liver cancer in late 2024, supporting planned regulatory submissions; additionally, it secured non-dilutive funding through a $5.1 million NIH grant in 2025 for further Namodenoson development in NASH.
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients
Wall Street is Watching These Biotechs
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds